Lunsumio Injection Dosage

Generic name: MOSUNETUZUMAB 30mg in 30mL
Dosage form: injection, concentrate
Drug class: Miscellaneous antineoplastics

Medically reviewed by Drugs.com. Last updated on Dec 22, 2022.

Important Dosing Information

Administer LUNSUMIO to well-hydrated patients.
Premedicate before each dose in Cycle 1 and Cycle 2 [see Dosage and Administration (2.2)].
Administer only as an intravenous infusion through a dedicated infusion line. Do not use an in-line filter to administer LUNSUMIO. Drip chamber filters can be used to administer LUNSUMIO.
LUNSUMIO should only be administered by a qualified healthcare professional with appropriate medical support to manage severe reactions such as cytokine release syndrome and neurologic toxicity [see Warnings and Precautions (5.1 and 5.2)].

Recommended Dosage

The recommended dosage for LUNSUMIO is presented in Table 1.

Administer for 8 cycles, unless patients experience unacceptable toxicity or disease progression.

For patients who achieve a complete response, no further treatment beyond 8 cycles is required. For patients who achieve a partial response or have stable disease in response to treatment with LUNSUMIO after 8 cycles, an additional 9 cycles of treatment (17 cycles total) should be administered, unless a patient experiences unacceptable toxicity or disease progression.

Table 1. Recommended LUNSUMIO Dose and Schedule (21-Day Treatment Cycles)
Day of Treatment		Dose of LUNSUMIO	Rate of Infusion
Cycle 1	Day 1	1 mg	Administer over a minimum of 4 hours.
	Day 8	2 mg
	Day 15	60 mg
Cycle 2	Day 1	60 mg	Administer over 2 hours if infusions from Cycle 1 were well-tolerated.
Cycles 3+	Day 1	30 mg

Table 2. Recommendations for Restarting Therapy with LUNSUMIO After Dose Delay
Last Dose Administered	Time Since the Last Dose Administered	Action for Next Dose(s)
* For the Day 1, Day 8, and Day 15 doses in the next cycle, administer premedication as per Table 3 for all patients
1 mg Cycle 1 Day 1	1 to 2 weeks	Administer 2 mg (Cycle 1 Day 8), then resume the planned treatment schedule.
1 mg Cycle 1 Day 1	Greater than 2 weeks	Repeat 1 mg (Cycle 1 Day 1), then administer 2 mg (Cycle 1 Day 8) and resume the planned treatment schedule.
2 mg Cycle 1 Day 8	1 to 2 weeks	Administer 60 mg (Cycle 1 Day 15), then resume the planned treatment schedule.
	Greater than 2 weeks to less than 6 weeks	Repeat 2 mg (Cycle 1 Day 8), then administer 60 mg (Cycle 1 Day 15) and resume the planned treatment schedule.
	Greater than or equal to 6 weeks	Repeat 1 mg (Cycle 1 Day 1) and 2 mg (Cycle 1 Day 8), then administer 60 mg (Cycle 1 Day 15) and resume the planned treatment schedule.
60 mg Cycle 1 Day 15	1 week to less than 6 weeks	Administer 60 mg (Cycle 2 Day 1), then resume the planned treatment schedule.
60 mg Cycle 1 Day 15	Greater than or equal to 6 weeks	Repeat 1 mg (Cycle 2 Day 1) and 2 mg (Cycle 2 Day 8), then administer 60 mg (Cycle 2 Day 15), followed by 30 mg (Cycle 3 Day 1) and then resume the planned treatment schedule.
60 mg Cycle 2 Day 1	3 weeks to less than 6 weeks	Administer 30 mg (Cycle 3 Day 1), then resume the planned treatment schedule.
60 mg Cycle 2 Day 1	Greater than or equal to 6 weeks	Repeat 1 mg (Cycle 3 Day 1) and 2 mg (Cycle 3 Day 8), then administer 30 mg (Cycle 3 Day 15)*, followed by 30 mg (Cycle 4 Day 1) and then resume the planned treatment schedule.
30 mg Cycle 3 onwards	3 weeks to less than 6 weeks	Administer 30 mg, then resume the planned treatment schedule.
30 mg Cycle 3 onwards	Greater than or equal to 6 weeks	Repeat 1 mg on Day 1 and 2 mg on Day 8 during the next cycle, then administer 30 mg on Day 15*, followed by 30 mg on Day 1 of subsequent cycles.

Recommended Premedication and Prophylactic Medication

Premedication to reduce the risk of cytokine release syndrome and infusion-related reactions are outlined in Table 3 [see Warnings and Precautions (5.1)].

Table 3. Premedication to be Administered to Patients Prior to LUNSUMIO Infusion
Treatment Cycle	Patients Requiring Premedication	Premedication	Dosage	Administration
Cycle 1 and Cycle 2	All patients	Corticosteroid	Dexamethasone 20 mg intravenous or methylprednisolone 80 mg intravenous	Complete at least 1 hour prior to infusion
		Antihistamine	Diphenhydramine hydrochloride 50 mg – 100 mg or equivalent oral or intravenous antihistamine	At least 30 minutes prior to infusion
		Antipyretic	Oral acetaminophen (500 mg – 1,000 mg)	At least 30 minutes prior to infusion
Cycles 3+	Patients who experienced any grade CRS with the previous dose	Corticosteroid	Dexamethasone 20 mg intravenous or methylprednisolone 80 mg intravenous	Complete at least 1 hour prior to infusion
		Antihistamine	Diphenhydramine hydrochloride 50 mg – 100 mg or equivalent oral or intravenous antihistamine	At least 30 minutes prior to infusion
		Antipyretic	Oral acetaminophen (500 mg – 1,000 mg)	At least 30 minutes prior to infusion

Dosage Modifications for Adverse Reactions

See Tables 4 and 5 for the recommended dosage modifications for adverse reactions of CRS and neurologic toxicity, including Immune Effector Cell Associated Neurotoxicity (ICANS). See Table 6 for the recommended dosage modifications for other adverse reactions following administration of LUNSUMIO.

Dosage Modifications for Cytokine Release Syndrome

Identify cytokine release syndrome (CRS) based on clinical presentation [see Warnings and Precautions (5.1)]. Evaluate for and treat other causes of fever, hypoxia, and hypotension.

If CRS is suspected, withhold LUNSUMIO until CRS resolves, manage according to the recommendations in Table 4 and per current practice guidelines. Administer supportive therapy for CRS, which may include intensive care for severe or life-threatening CRS.

Table 4. Recommendations for Management of Cytokine Release Syndrome
Grade*	Presenting Symptoms	Actions†
* Based on American Society for Transplantation and Cellular Therapy (ASTCT) 2019 grading for CRS. † If CRS is refractory to management, consider other causes including hemophagocytic lymphohistiocytosis. ‡ Premedication may mask fever, therefore if clinical presentation is consistent with CRS, follow these management guidelines. § Refer to Table 2 for information on restarting LUNSUMIO after dose delays [see Dosage and Administration (2.2)]. ¶ Refer to Table 3 for additional information on premedication. # Low-flow oxygen defined as oxygen delivered at < 6 L/minute; high-flow oxygen defined as oxygen delivered at ≥ 6 L/minute.
Grade 1	Fever ≥ 100.4°F (38°C)‡	Withhold current infusion of LUNSUMIO and manage per current practice guidelines. If symptoms resolve, restart infusion at the same rate. Ensure CRS symptoms are resolved for at least 72 hours prior to the next dose of LUNSUMIO.§ Administer premedication¶ prior to next dose of LUNSUMIO and monitor patient more frequently.
Grade 2	Fever ≥ 100.4°F (38°C)‡ with: Hypotension not requiring vasopressors and/or hypoxia requiring low-flow oxygen# by nasal cannula or blow-by.	Withhold current infusion of LUNSUMIO and manage per current practice guidelines. If symptoms resolve, restart infusion at 50% rate. Ensure CRS symptoms are resolved for at least 72 hours prior to the next dose of LUNSUMIO.§ Administer premedication¶ prior to next dose of LUNSUMIO and consider infusing the next dose at 50% rate. For the next dose of LUNSUMIO, monitor more frequently and consider hospitalization.
Grade 2		Recurrent Grade 2 CRS Manage per Grade 3 CRS.
Grade 3	Fever ≥ 100.4°F (38°C)‡ with: Hypotension requiring a vasopressor (with or without vasopressin) and/or hypoxia requiring high flow oxygen# by nasal cannula, face mask, non-rebreather mask, or Venturi mask.	Withhold LUNSUMIO, manage per current practice guidelines and provide supportive therapy, which may include intensive care. Ensure CRS symptoms are resolved for at least 72 hours prior to the next dose of LUNSUMIO.§ Administer premedication¶ prior to next dose of LUNSUMIO and infuse the next dose at 50% rate. Hospitalize for the next dose of LUNSUMIO.
Grade 3		Recurrent Grade 3 CRS Permanently discontinue LUNSUMIO. Manage CRS per current practice guidelines and provide supportive therapy, which may include intensive care.
Grade 4	Fever ≥ 100.4°F (38°C)‡ with: Hypotension requiring multiple vasopressors (excluding vasopressin) and/or hypoxia requiring oxygen by positive pressure (e.g., CPAP, BiPAP, intubation and mechanical ventilation).	Permanently discontinue LUNSUMIO. Manage CRS per current practice guidelines and provide supportive therapy, which may include intensive care.

Dosage Modifications for Neurologic Toxicity, including ICANS

Management recommendations for neurologic toxicity, including ICANS, is summarized in Table 5. At the first sign of neurologic toxicity, including ICANS, withhold LUNSUMIO and consider neurology evaluation. Rule out other causes of neurologic symptoms. Provide supportive therapy, which may include intensive care.

Table 5. Recommendations for Management of Neurologic Toxicity (including ICANS)
Adverse Reaction	Severity*,†	Actions
* Based on National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 4.0. † Based on American Society for Transplantation and Cellular Therapy (ASTCT) 2019 grading for ICANS. ‡ See Table 2 for recommendations on restarting LUNSUMIO after dose delays [see Dosage and Administration (2.2)].
Neurologic Toxicity* (Including ICANS†)	Grade 2	Withhold LUNSUMIO until neurologic toxicity symptoms improve to Grade 1 or baseline for at least 72 hours.‡ Provide supportive therapy. If ICANS, manage per current practice guidelines.
	Grade 3	Withhold LUNSUMIO until neurologic toxicity symptoms improve to Grade 1 or baseline for at least 72 hours.‡ Provide supportive therapy, which may include intensive care, and consider neurology evaluation. If ICANS, manage per current practice guidelines. If recurrence, permanently discontinue LUNSUMIO.
	Grade 4	Permanently discontinue LUNSUMIO. Provide supportive therapy, which may include intensive care, and consider neurology evaluation. If ICANS, manage per current practice guidelines.

Table 6. Recommended Dosage Modification for Other Adverse Reactions
Adverse Reactions*	Severity*	Actions
* Based on National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 4.0. † See Table 2 for recommendations on restarting LUNSUMIO after dose delays [see Dosage and Administration (2.2)].
Infections [see Warnings and Precautions (5.3)]	Grades 1 – 4	Withhold LUNSUMIO in patients with active infection until the infection resolves.† For Grade 4, consider permanent discontinuation of LUNSUMIO.
Neutropenia [see Warnings and Precautions (5.4)]	Absolute neutrophil count less than 0.5 × 109/L	Withhold LUNSUMIO until absolute neutrophil count is 0.5 × 109/L or higher.†
Other Adverse Reactions [see Warnings and Precautions (5.5) and Adverse Reactions (6.1)]	Grade 3 or higher	Withhold LUNSUMIO until the toxicity resolves to Grade 1 or baseline.†

Preparation and Administration

Preparation

Use aseptic technique to prepare LUNSUMIO.

Inspect the vial visually for any particulate matter, prior to administration. Do not use if the solution is discolored, or cloudy, or if foreign particles are present.
Determine the dose, the total volume of LUNSUMIO solution required, and the number of LUNSUMIO vials needed.

Dilution

1.: Withdraw the volume from an infusion bag of 0.9% Sodium Chloride Injection, USP or 0.45% Sodium Chloride Injection, USP equal to the volume of the LUNSUMIO required for the patient's dose and discard. Only use infusion bags made of polyvinyl chloride (PVC) or polyolefin (PO) such as polyethylene (PE) and polypropylene.
2.: Withdraw the required volume of LUNSUMIO from the vial using a sterile needle and syringe and dilute into the infusion bag of 0.9% Sodium Chloride Injection, USP or 0.45% Sodium Chloride Injection, USP according to Table 7. Discard any unused portion left in the vial.

Table 7. Dilution of LUNSUMIO
Dose of LUNSUMIO	Volume of LUNSUMIO in 0.9% or 0.45% Sodium Chloride Solution	Size of Infusion Bag
1 mg	1 mL	50 mL or 100 mL
2 mg	2 mL	50 mL or 100 mL
60 mg	60 mL	100 mL or 250 mL
30 mg	30 mL	50 mL, 100 mL, or 250 mL

3.: Gently mix the intravenous bag by slowly inverting the bag. Do not shake.
4.: Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Do not use if visibly opaque particles, discoloration, or foreign particles are observed.
5.: Apply the peel-off label from the package insert to the infusion bag.
6.: Immediately use diluted LUNSUMIO infusion solution. If not used immediately, the diluted solution can be stored refrigerated at 2°C to 8°C (36°F to 46°F) for up to 24 hours and at ambient temperature 9°C to 30°C (48°F to 86°F) for up to 16 hours. Prior to administration, ensure the infusion solution comes to reach room temperature.

Administration

Administer as an intravenous infusion only.
Do not use an in-line filter to administer LUNSUMIO.
Do not mix LUNSUMIO with, or administer through the same infusion line, as other medicinal products.
No incompatibilities have been observed between LUNSUMIO and intravenous infusion bags with product contacting materials of polyvinyl chloride (PVC), or polyolefins (PO) such as polyethylene (PE) and polypropylene (PP). In addition, no incompatibilities have been observed with infusion sets or infusion aids with product contacting materials of PVC, PE, polyurethane (PUR), polybutadiene (PBD), silicone, acrylonitrile butadiene styrene (ABS), polycarbonate (PC), polyetherurethane (PEU), fluorinated ethylene propylene (FEP), or polytetrafluorethylene (PTFE), or with drip chamber filter membrane composed of polyamide (PA).